Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here  to learn how we are responding.

Congress Materials

Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Oral Presentation
Dholaria B, Bahlis NJ, Raje NS, Costello CL, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Lon HK, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM September 8, 2021 IMW 2021 Hematology

MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)

View Presentation View Abstract Plain Language Summary
Poster
Gambacorti-Passerini C, Brummendorf TH, Abruzzese E, Kelly KR, Oehler VG, Garcia-Gutierrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles F, Hochhaus A December 11, 2021 ASH 2021 Hematology

Efficacy and Safety of Bosutinib in Previously Treated Patients With Chronic Myeloid Leukemia: Final Results From the BYOND Trial

View Presentation
Poster
Lesokhin AM, Iida S, Stevens D, Gabayan AE, Ma WD, Sullivan S, Raab MS December 11, 2021 ASH 2021 Hematology

MagnetisMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Özcan M, Cassaday RD, Singh P, Zarzycka E, Zhang X, Nègre E, Vandendries E, Altunas F December 11, 2021 ASH 2021 Hematology

The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

View Presentation View Abstract Plain Language Summary
Poster
Pennesi E, Brivio E, Willemse ME, Huitema ADR, Chandra S, Vijayakumar A, Van Der Velden VHJ, Beverloo BH, Durairaj C, Viqueira A, Locatelli F, Motwani J, Bourquin JP, Bautista F, Rizzari C, Petit A, Lancaster D, Metzler M, Bertrand Y, Velasco P, Bukowkinski AJ, Krystal J, Van Der Sluis I, Van Tinteren H, Roth M, Hijiya N, Zwaan CM December 12, 2021 ASH 2021 Hematology

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

View Presentation
Poster
Crawford R, Welch V, Shah R, Doward L, Truchan C December 12, 2021 ASH 2021 Hematology

A pilot study of the application of natural language interpretation to identify insights on acute lymphocytic leukemia and its treatment from social media data

View Presentation View Abstract Plain Language Summary
Poster
Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, Sekiguchi N, Ono C, Aizawa M, Tanetsugu Y, Koide Y, Takahashi N December 12, 2021 ASH 2021 Hematology

Efficacy and Safety of Bosutinib in Japanese Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

View Presentation View Abstract Plain Language Summary
Oral Presentation
Sebag M, Raje NS, Bahlis NJ, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Lon HK, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Dalovisio A, Lesokhin AM December 13, 2021 ASH 2021 Hematology

MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted CD3-Engaging Bispecific Molecule, for Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Oral Presentation
Zhao Y, Laird AD, Roberts K, Yafawi R, Kantarjian H, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O’Brien S, Jabbour E, Cassaday RD, Loyd MR, Olsen S, Neale G, Liu X, Vandendries E, Mullighan CG, Advani A April 10, 2022 AACR 2022 Hematology

Exploration of Association of Leukemic Molecular Profile with Efficacy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin in the Phase 3 INO-VATE Trial

View Presentation View Abstract Plain Language Summary
Poster
Cortes JE,  Milojkovic D,  Gambacorti-Passerini C,  García-Gutiérrez V,  Mauro MJ,  Leip E, Purcell S,  Viqueira A,  Brümmendorf TH June 4, 2022 ASCO 2022 Hematology

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

View Presentation View Abstract Plain Language Summary